Literature DB >> 20935024

Psychostimulant treatment of combat-related posttraumatic stress disorder.

David J Houlihan1.   

Abstract

The objective of this paper is to describe three cases of combat-related posttraumatic stress disorder (PTSD), largely refractory to standard medication treatment who responded well to psychostimulant treatment. Symptoms of PTSD potentially result from chronic, stress-induced dopaminergic dysfunction in the prefrontal cortex/basal ganglia system. Psychostimulants, by their relative propensity to enhance dopamine (DA) activity within these brain regions, may have particular value in targeting this dysfunction. Evidence of dopaminergic dysfunction following chronic stress is reviewed and possible mechanism of action of psychostimulants is explored. Psychostimulants appeared to be well tolerated and beneficial in the treatment of the cases of combat-related PTSD reported. General applicability of the use of psychostimulants in combat- and non-combat-related PTSD awaits further study. The potential implications of these findings in further delineating pathophysiology and treatment in PTSD deserve further exploration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20935024     DOI: 10.1177/0269881110385600

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  9 in total

Review 1.  Ventral Tegmental Area Dysfunction and Disruption of Dopaminergic Homeostasis: Implications for Post-traumatic Stress Disorder.

Authors:  Peiling Zhou; Meiping Deng; Jiashan Wu; Qinghui Lan; Huifang Yang; Changzheng Zhang
Journal:  Mol Neurobiol       Date:  2021-01-11       Impact factor: 5.590

Review 2.  Connecting the pathology of posttraumatic stress and substance use disorders: monoamines and neuropeptides.

Authors:  Nicole M Enman; Yong Zhang; Ellen M Unterwald
Journal:  Pharmacol Biochem Behav       Date:  2013-12-11       Impact factor: 3.533

3.  Involvement of the ventral tegmental area in a rodent model of post-traumatic stress disorder.

Authors:  Nadia S Corral-Frias; Ryan P Lahood; Kimberly E Edelman-Vogelsang; Edward D French; Jean-Marc Fellous
Journal:  Neuropsychopharmacology       Date:  2012-09-26       Impact factor: 7.853

4.  Methylphenidate enhances extinction of contextual fear.

Authors:  Antony D Abraham; Christopher L Cunningham; K Matthew Lattal
Journal:  Learn Mem       Date:  2012-01-17       Impact factor: 2.460

Review 5.  Dopamine and extinction: a convergence of theory with fear and reward circuitry.

Authors:  Antony D Abraham; Kim A Neve; K Matthew Lattal
Journal:  Neurobiol Learn Mem       Date:  2013-11-20       Impact factor: 2.877

6.  Practical use and risk of modafinil, a novel waking drug.

Authors:  Dongsoo Kim
Journal:  Environ Health Toxicol       Date:  2012-02-22

7.  Psychostimulants for the Treatment of Comorbid Post-traumatic Stress Disorder (PTSD) in a Patient With Attention-Deficit/Hyperactivity Disorder (ADHD): A Case Report and Literature Summary.

Authors:  Claudette Barreto; Ana Vila Irigoyen; Olga Lopez; Leonard Gralnik
Journal:  Cureus       Date:  2022-08-20

8.  Methylphenidate and desipramine combined treatment improves PTSD symptomatology in a rat model.

Authors:  S Aga-Mizrachi; A Cymerblit-Sabba; O Gurman; A Balan; G Shwam; R Deshe; L Miller; N Gorodetsky; N Heinrich; O Tzezana; S Zubedat; D Grinstein; A Avital
Journal:  Transl Psychiatry       Date:  2014-09-23       Impact factor: 6.222

Review 9.  Therapeutic Challenges of Post-traumatic Stress Disorder: Focus on the Dopaminergic System.

Authors:  Sebastiano Alfio Torrisi; Gian Marco Leggio; Filippo Drago; Salvatore Salomone
Journal:  Front Pharmacol       Date:  2019-04-17       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.